RS20230516A1 - Postupci za lečenje raka prostate - Google Patents

Postupci za lečenje raka prostate

Info

Publication number
RS20230516A1
RS20230516A1 RS20230516A RSP20230516A RS20230516A1 RS 20230516 A1 RS20230516 A1 RS 20230516A1 RS 20230516 A RS20230516 A RS 20230516A RS P20230516 A RSP20230516 A RS P20230516A RS 20230516 A1 RS20230516 A1 RS 20230516A1
Authority
RS
Serbia
Prior art keywords
prostate cancer
methods
treating prostate
treating
castrate
Prior art date
Application number
RS20230516A
Other languages
English (en)
Inventor
Sarah Deborah Chirnomas
Richard Walter Gedrich
Ronald Peck
Ian Charles Anthony Taylor
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of RS20230516A1 publication Critical patent/RS20230516A1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Predmetna prijava se odnosi na lečenje i/ili prevenciju raka prostate, uključujući metastaski i/ili rak prostate otporan na kastrate, kod subjekta kome je potrebno lečenje, a koji ima određeni status biomarkera somatskog AR tumora, i koje obuhvata davanje jedinjenja Formule (I), ili njegove farmaceutski prihvatljive soli, enantiomera, stereoizomera, solvata, polimorfa, izotopskog derivata ili proleka, pri čemu su R1, R2, R3, X1, X2, X3, X4 i n ovde definisani.
RS20230516A 2020-12-11 2021-12-10 Postupci za lečenje raka prostate RS20230516A1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063124640P 2020-12-11 2020-12-11
US202063125345P 2020-12-14 2020-12-14

Publications (1)

Publication Number Publication Date
RS20230516A1 true RS20230516A1 (sr) 2023-08-31

Family

ID=80112368

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230516A RS20230516A1 (sr) 2020-12-11 2021-12-10 Postupci za lečenje raka prostate

Country Status (11)

Country Link
US (2) US20220184078A1 (sr)
EP (1) EP4259142A1 (sr)
JP (1) JP2023552818A (sr)
KR (1) KR20230118147A (sr)
AU (1) AU2021398565A1 (sr)
CA (1) CA3204819A1 (sr)
CL (1) CL2023001655A1 (sr)
IL (1) IL303231A (sr)
MX (1) MX2023006883A (sr)
RS (1) RS20230516A1 (sr)
WO (1) WO2022125969A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3660004T3 (pl) * 2016-10-11 2023-10-02 Arvinas Operations, Inc. Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
WO2023205481A1 (en) * 2022-04-21 2023-10-26 Arvinas Operations, Inc. A combination for use in treating prostate cancer comprising arv-100 and abiraterone
WO2024054602A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024091975A1 (en) * 2022-10-24 2024-05-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
PL3660004T3 (pl) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
EP4048236A1 (en) * 2019-10-22 2022-08-31 Arvinas Operations, Inc. Methods of treating prostate cancer
IL297823A (en) * 2020-05-12 2023-01-01 Arvinas Operations Inc Prostate cancer treatment methods

Also Published As

Publication number Publication date
CA3204819A1 (en) 2022-06-16
IL303231A (en) 2023-07-01
AU2021398565A1 (en) 2023-06-29
WO2022125969A1 (en) 2022-06-16
CL2023001655A1 (es) 2023-12-15
JP2023552818A (ja) 2023-12-19
KR20230118147A (ko) 2023-08-10
US20220184078A1 (en) 2022-06-16
EP4259142A1 (en) 2023-10-18
US20240066032A1 (en) 2024-02-29
MX2023006883A (es) 2023-06-23

Similar Documents

Publication Publication Date Title
RS20230516A1 (sr) Postupci za lečenje raka prostate
MX2022004808A (es) Métodos para tratar el cáncer de próstata.
MX2022014192A (es) Metodos para tratar el cancer de prostata.
MX2022002415A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2021011606A (es) Compuestos dirigidos a prmt5.
WO2007038868A3 (en) Novel enediyne compound and uses thereof
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
TW201613589A (en) Combination methods for treating cancers
MX2020010437A (es) Inhibidores de axl cinasa y uso de los mismos.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
TNSN07294A1 (en) Treatment of metastasized tumors
MX2022016554A (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
JOP20200244A1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
MX2021012105A (es) Compuestos de pirrol.
RU2011148954A (ru) Замещенные пирролидином флавоны в качестве радиосенсибилизаторов для применения при лечении рака
TW200512198A (en) 5-arylpyrimidines as anticancer agents
MX2023007058A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
MX2021009206A (es) Terapias contra el cancer.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2023141432A3 (en) Apol1 inhibitors and methods of use